MRK.US Weekly Report · 2026-W35
Since mid-August, Merck has surged significantly on the back of clinical breakthroughs in cancer vaccines. This week (Aug 24-29), the stock rallied from 150.66 to 148.35, gaining 9.74% weekly. Following a sharp 12.6% jump on August 19, the stock entered high-level consolidation. A tension emerges between profit headwinds (negative EPS in recent two quarters) and cancer vaccine commercial potential, with institutional support contrasting against persistent capital outflows, signaling divergence in market sentiment.
Price Action
This week’s close at 148.35 represents a 2.8% decline from the prior week’s close (August 22 at 152.55), yet reflects an 18.3% advance from the beginning of August (August 1 close at 125.37). Intra-week range was 10.3% (high 149.01 to low 145.75), with daily volume of 8.19 million shares, approximately 15% above the 60-day median volume, indicating moderate accumulation.
August 19 marked a pivotal inflection point, with a single-day surge to 152.20 (+12.6%), accompanied by volume spike of 32.77 million shares (highest in 60 days). The stock entered a wide consolidation pattern, peaking at 156.45 on August 25 before retreating to current levels. The past two trading days showed shrinking volume during the pullback, typical of profit-taking after steep rallies.
Valuation and Earnings
The current P/E of 115.35x stands at an historically depressed level. Based on valuation data, this metric has been lower than the current reading for only 1.29% of trading days over the past five years—essentially representing the lowest valuation in a five-year horizon. This extreme discount reflects market skepticism about near-term earnings recovery.
Recent earnings data reveals a profitability crisis. Q2 2026 EPS came in at -$0.54 (loss), a marginal improvement from Q1’s -$1.72 but still deep negative. Against consensus EPS expectation of $8.617, the actual result signals a shortfall exceeding 200%. Revenue showed relative resilience: Q2 operating revenue of $16.607 billion grew 1.4% quarter-on-quarter and 5.07% year-over-year. However, net profit deteriorated to -$1.335 billion in Q2 (from -$4.24 billion in Q1), with ROE registering -12.16% and -34.44% respectively—two consecutive quarters of red ink reflect structural headwinds requiring vaccine-driven turnaround.
The disconnect between rock-bottom valuation and consecutive losses underscores investor focus on whether cancer vaccine commercialization can reverse earnings trajectory.
Capital Flows and Institution Views
This week exhibited broad-based capital outflows. Retail investors recorded net outflows (inflows 4682.01 vs outflows 6594.44), while large institutions also showed minor net selling (inflows 1042.09 vs outflows 1066.99). Mid-sized players also net exited. Despite the stock hitting multi-week highs, all investor classes selectively reduced positions—a stark contrast with institutional enthusiasm.
Institution ratings remain constructive: 15 buy ratings, 8 hold ratings, and 5 sell ratings. Consensus recommendation is “Buy” with a target price of $148.73, leaving limited upside at current levels. Notably, the last rating update was August 25; the two-day pullback that followed illustrates typical valuation lag in institutional guidance.
Weekly News Themes
News flow centered on three threads: cancer vaccine breakthrough, share price momentum, and regulatory clarity:
-
Cancer Vaccine Milestone: August 19 coverage announced that Moderna and Merck’s mRNA cancer vaccine achieved the first positive Phase 3 data—a historic first after a century of failed attempts. This drove Merck’s 12.6% single-day gain. Follow-up reporting detailed vaccine mechanics and commercialization hurdles.
-
Price Action and Capital Events: Reports tracked Merck’s new highs, institutional target price upgrades (Argus raising to $170), and block trades (ABN AMRO reducing position).
-
Regulatory Clarity: Court ruling rejected Merck’s challenge to Medicare drug price negotiation program, removing policy uncertainty.
Reference News:
- Pharmaceutical Stocks Worth Watching - August 28th
- FOCUS-Success after a century of failures: Inside Moderna and Merck’s cancer vaccine breakthrough
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- EXPLAINER-How the Merck/Moderna cancer vaccine works and possible barriers to wide use
- Merck hits record high after Argus hikes target to $170 on cancer vaccine progress
- Dow Up 136 Points On Gains For Shares Of Merck, Goldman Sachs
- Merck & Co Inc Stock (MRK) Moved Up by 3.76% on Aug 25: A Full Analysis
- Argus Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock
- Court Rejects Merck’s Challenge to Medicare Drug Price Negotiation Program
- Nike, Merck Share Losses Contribute To Dow’s 150-Point Drop
Signal Consistency Analysis
Marked signal divergence emerged this week. Valuation (P/E at 1st percentile over five years) and institutional ratings (15 buy ratings) align bullishly, betting that cancer vaccine commercialization reverses earnings. Conversely, back-to-back quarters of negative EPS combined with universal capital outflows signal real-time skepticism—investors are voting with their feet against the “cheap + rated buy” thesis. This friction typically precedes price weakness when lagging signals normalize. The court victory on Medicare pricing removes policy uncertainty but leaves earnings headwinds unresolved. The critical variable becomes vaccine commercialization timeline and contribution to profitability; near-term earnings recovery remains the clock on sentiment.